Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 121 Matches

Curcumin_Japanese_V19R1_AstraZeneca_20210726
Model Files Publication
For curcumin, the Japanese population library file from the Simcyp Human Simulator was used, and a sulfotransferase clearance pathway was incorporated as published for the curcumin PBPK model (Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect - PubMed (nih.gov)). The curcumin model used in the publication linked is also based on this earlier published model. Fugut=1 represents worst-case scenario DDI while Fugut=0.03 represents assumption that fu,gut = fu,whole blood.
Search Score: 1
V21R1_BisphenolA_JagiellonianUniversity_20230711
Model Files Publication
The dataset can be found at the following URL: https://data.mendeley.com/datasets/t7t8kbjpyg/1
Search Score: 1
Primaquine
Model Files Publication

Brand Name(s) include: Jasoprim, Malirid, Neo-Quipenyl, Pimaquin, Pmq, Primachina, Primacin, Primaquina, Primaquine, Primaquine diphosphate, Primaquine Phosphate, and Remaquin

Disease: Malaria, Plasmodium vivax, Plasmodium ovale

Drug Class: Antimalarial

Related Files: Carboxyprimaquine (metabolite)

Date Updated: March 2022

 The model at-a-glance

Absorption Model
  • First-Order

Volume of Distribution 
  • Full PBPK (Method 2)

Routes of Elimination
  • 89% MAO (entered using ‘user-UGT’ as a surrogate in the Simulator), 11% CYP2D6

Perpetrator DDI
  • CYP1A2 Inhibitor (in vitro)

Validation

  •  6 studies with single (15 to 45 mg) and multiple (15 mg QD) dosing. 100% of Cmax and AUC values within 1.5-fold.
  • No clinical DDI studies to verify contribution of metabolic routes

Limitations
  •  The active metabolites of primaquine have not characterized due to their instability. Therefore, a PBPK model for active metabolites cannot be developed in their own right.
  • Qualitative data suggests a role of P-gp, however, Jmax and Km values have not been measured.
  • There is evidence of enantiomer specific metabolism for primaquine which has not been considered in the current model.

Updates in Version 19
  • Updated in vitro protein and blood binding data and subsequent back calculation of CLint (retrograde approach)
    •  fu: 0.19 -> 0.26
    • B:P: 1 -> 0.82
  • Converted from minimal PBPK model to full PBPK model

 

Search Score: 1
Aprepitant_RES_V19R1_Simcyp_20200205
Model Files Publication

Simcyp developed Aprepitant compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.

Search Score: 1

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|